These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356 [TBL] [Abstract][Full Text] [Related]
3. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720 [TBL] [Abstract][Full Text] [Related]
4. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Tanaka S; Matsuo K; Sasaki T; Nakano M; Sakai K; Beppu R; Yamashita Y; Maeda K; Aoyagi K Hepatogastroenterology; 2010; 57(97):3-7. PubMed ID: 20422862 [TBL] [Abstract][Full Text] [Related]
6. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797 [TBL] [Abstract][Full Text] [Related]
15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
16. The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease. Haennig A; Staumont G; Lepage B; Faure P; Alric L; Buscail L; Bournet B; Moreau J Colorectal Dis; 2015 Apr; 17(4):311-9. PubMed ID: 25425534 [TBL] [Abstract][Full Text] [Related]
17. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340 [TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment for anal fistula in patients with Crohn's disease. Higashi D; Futami K; Egawa Y; Hirano K; Tomiyasu T; Ishibashi Y; Simomura T; Nii K; Kuroki H; Maekawa T; Ono Y; Matsui T Anticancer Res; 2009 Mar; 29(3):927-33. PubMed ID: 19414329 [TBL] [Abstract][Full Text] [Related]
19. Local injection of Infliximab for the treatment of perianal Crohn's disease. Poggioli G; Laureti S; Pierangeli F; Rizzello F; Ugolini F; Gionchetti P; Campieri M Dis Colon Rectum; 2005 Apr; 48(4):768-74. PubMed ID: 15768185 [TBL] [Abstract][Full Text] [Related]
20. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]